Jonathan A. Gutman

University of Colorado Denver — United States

Medicine · Health Sciences

39h-index11.2kcitations220works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(79), Hematopoietic Stem Cell Transplantation(68), Chronic Myeloid Leukemia Treatments(32), Polyomavirus and related diseases(26), Acute Lymphoblastic Leukemia research(24)

Publications220 total

Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy
Haematologica·2026Open Access
Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia
American Journal of Hematology·2026
RNA fusion sequencing identifies clinically relevant and novel fusions with therapeutic implications in adults with Acute Myeloid Leukemia (AML)
Blood·2025
UCD19 CAR-T cell therapy for adults with B-cell acute lymphoblastic leukemia in first complete remission with MRD positivity: Preliminary Results of A phase I/ib clincal trial
Blood·2025Open Access
The impact of monocytic phenotype and NPM1-mutation status in Acute Myeloid Leukemia when treated with traditional induction chemotherapy compared to azacitidine and venetoclax
Blood·2025Open Access
Patients with AML with an IDH2 R172K mutation have improved overall survival with venetoclax + azacitidine as compared to those with IDH2 R140Q mutations
Blood·2025
Next-generation sequencing (NGS) of DNA isolated from nail specimens and run in parallel with tumor NGS accurately and efficiently detects germline predisposition variants in myeloid malignancies
Blood·2025Open Access
Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial
EClinicalMedicine·2025Open Access
Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network·2025· 4 cited
Impact of demographic factors on clinical outcomes of patients with acute myeloid leukemia
Haematologica·2025Open Access
Known Prognostic Models Fail to Predict Outcomes for Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia: A Single‐Center Retrospective Analysis
American Journal of Hematology·2025Open Access
Risk Factors for Solid Organ Graft Failure and Death in Solid Organ Transplant Recipients Undergoing Hematopoietic Cell Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research (CIBMTR) and Organ Procurement and Transplantation Network (OPTN) Study
Transplantation·2025· 1 citedOpen Access
Risk Factors for Solid Organ Graft Failure and Death in Hematopoietic Cell Transplant Recipients Undergoing Solid Organ Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research and Organ Procurement and Transplantation Network Study
Transplantation·2025Open Access
Outcomes for adults with KMT2A-r acute myeloid leukemia treated with venetoclax plus azacitidine (Ven/Aza) or intensive chemotherapy (IC): A single-center retrospective study.
Journal of Clinical Oncology·2025
Tolerability and outcomes with serial cycles of 28 days of venetoclax in newly diagnosed patients with AML.
Journal of Clinical Oncology·2025
Comparison of treatment-related and de novo CCUS: a retrospective analysis from two centers
Leukemia & lymphoma/Leukemia and lymphoma·2025
Comparison of Myeloablative Conditioning with a Total Body Irradiation-Based Regimen Versus a Chemotherapy-Based Regimen in Adult Patients Undergoing Umbilical Cord Blood Stem Cell Transplant for Ph-Negative Acute Lymphoblastic Leukemia
Transplantation and Cellular Therapy·2025
Successful Generation of Anti-CD19 CAR T-Cells (KYV-101) for Clinical Use in Patients with Clinically Diverse Autoimmune Disorders
Transplantation and Cellular Therapy·2025
Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts
Blood·2024Open Access
Treatment-Related and De Novo Ccus Have Similar Molecular Features and Risk of Progression to Myeloid Malignancies
Blood·2024
page 1 of 11Next →

Frequent Co-authors

Daniel A. Pollyea(16), Clayton A. Smith(13), Craig T. Jordan(10), Amanda Winters(8), Diana Abbott(8), Colleen Delaney(8), Brett M. Stevens(6), Enkhtsetseg Purev(6), Jeffrey Schowinsky(5), Ann E. Woolfrey(5), Jennifer Tobin(5), Shanshan Pei(4), Frederick R. Appelbaum(4), Peter J. Fagenholz(4), Alice F. Murray(4), N. Stuart Harris(4), Thomas J. Reynolds(3), Mohammad Minhajuddin(3), Angelo D’Alessandro(3), Maria L. Amaya(3)